Fall in plasma ghrelin concentrations after cisplatin-based chemotherapy in esophageal cancer patients

International Journal of Clinical Oncology

Volumn 17, Issue 4, 2012, Pages 316-323

  Hiura, Yuichiro ^a   Takiguchi, Shuji ^a   Yamamoto, Kazuyoshi ^a   Kurokawa, Yukinori ^a   Yamasaki, Makoto ^a   Nakajima, Kiyokazu ^a   Miyata, Hiroshi ^a   Fujiwara, Yoshiyuki ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Cisplatin based chemotherapy; Dietary intake; Esophageal cancer; Plasma ghrelin; Rapid turnover protein; Visual analog scale

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GHRELIN; GROWTH HORMONE; LEPTIN; PREALBUMIN; RETINOL BINDING PROTEIN; TRANSFERRIN;

ADULT; ANEMIA; ANOREXIA; APPETITE; ARTICLE; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DIETARY INTAKE; ESOPHAGUS CANCER; FEMALE; GHRELIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; NUTRITIONAL STATUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TRANSFERRIN BLOOD LEVEL;

AGED; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; GHRELIN; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NUTRITIONAL STATUS; TRANSFERRINS; TREATMENT OUTCOME;

EID: 84867286561     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0289-0     Document Type: Article

References (48)

1. Kranzfelder M, Buchler P, Lange K et al (2010) Treatment options for squamous cell cancer of the esophagus: A systematic review of the literature. J Am Coll Surg 210:351-359
2. Bedenne L, Michel P, Bouche' O et al (2007) Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160-1168
3. Ajani JA, Barthel JS, Bekaii-Saab T et al (2008) Esophageal cancer. J Natl Compr Canc Netw 6:818-849
4. Akita H, Doki Y, Yano M et al (2009) Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: Additive association with prognosis. Dis Esophagus 22:291-297
5. Medical Research Council Oesophageal Cancer Working Group (2002) Surgical resection with and without chemotherapy in oesophageal cancer. Lancet 359:1727-1733
6. Yano M, Takachi K, Doki Y et al (2006) Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 19:158-163
7. Matsuyama J, Doki Y, Yasuda T et al (2007) The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery 141:570-580
8. Hesketh PJ, Van Belle S, Aapro M et al (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074-1080
9. Cubeddu LX, Hoffmann IS (1993) Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: Effects of antiemetics. J Clin Pharmacol 33:691-697
10. Butcher ME (1993) Global experience with ondansetron and future potential. Oncology 50:191-197
11. Kojima M, Hosoda H, Date Y et al (1999) Ghrelin is a growthhormone- releasing acylated peptide from stomach. Nature 402:656-660
12. Nakazato M, Murakami N, Date Y et al (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194-198
13. Van der Lely AJ, Tschop M, Heiman ML et al (2004) Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 25:426-457
14. Korbonits M, Goldstone AP, Gueorguiev M et al (2004) Ghrelin-A hormone with multiple functions. Front Neuroendocrinol 25:27-68
15. Akamizu T, Kangawa K (2006) Translation research on the clinical applications of ghrelin. Endocr J 53:585-591
16. Ariyasu H, Iwakura H, Yamada G et al (2008) Efficacy of ghrelin as a therapeutic approach for age related physiological changes. Endocrinology 149:3722-3728
17. Shintani M, Ogawa Y, Ebihara K et al (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227-232
18. Adachi S, Takiguchi S, Okada K et al (2010) Effects of ghrelin administration after total gastrectomy: A prospective, randomized, placebo-controlled phase II study.Gastroenterology 138:1312-1320
19. Yamamoto K, Takiguchi S, Miyata H et al (2010) Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery 141:31-38
20. Liu Y-L, Malik NM, Sanger GJ et al (2006) Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 58:326-333
21. Takeda H, Sadakane C, Hattori T et al (2008) Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 134:2004-2013
22. Shimakawa T, Naritaka Y, Asaka S et al (2008) Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer. Anticancer Res 28:2321-2326
23. Tanaka Y, Yoshida K, Sanada Y et al (2010) Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: A phase I dose-escalation study. Cancer Chemother Pharmacol 66:1159-1165
24. Takahashi H, Arimura Y, Yamashita K et al (2010) Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 1:122-128
25. CTCAE v4.0. https://cabig-kc.nci.nih.gov/Vocab/KC/index.php/ CTCAE
26. Japanese Society for Esophageal Diseases (2001) Guidelines for clinical and pathologic studies on carcinoma in the esophagus, 9th edn. Kanehara & Co., Ltd, Tokyo
27. Akamizu T, Shinomiya T, Irako T et al (2005) Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrinol Metab 90:6-9
28. Nonogaki K, Nozue K, Oka Y (2006) Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice. Endocrinology 147:5893-5900
29. Castejon AM, Paez X, Hernandez L et al (1999) Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: Comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 291:960-966
30. Cubeddu LX, Hoffmann IS, Fuenmayor NT et al (1992) Changes in serotonin metabolism in cancer patients: Its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 66:198-203
31. Barnes NM, Ge J, Jones WG et al (1990) Cisplatin-induced emesis: Preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine. Br J Cancer 62:862-864
32. Du Bois A, Vach W, Siebert C et al (1997) The relationship between parameters of serotonin metabolism and emetogenic potential of platinum-based chemotherapy regimens. Support Care Cancer 5:212-218
33. Wilder-Smith OHG, Borgeat A, Chappuis P et al (1993) Urinary serotonin metabolite excretion during cisplatin chemotherapy. Cancer 72:2239-2241
34. Latreille J,Pater J, JohnstonDet al (1998)Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 16:1174-1178
35. Olver I, Paska W, Depierre A et al (1996) A multicentre, doubleblind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol 9:945-952
36. Cocquyt V, Van Belle S, Reinhardt RR et al (2001) Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatininduced emesis. Eur J Cancer 37:835-842
37. Diemunsch P, Grelot L (2000) Potential of substance P antagonists as antiemetics. Drugs 60:535-546
38. Gerald MH, Miklos LA, Ramin A et al (2006) 5-Hydroxyindoleacetic acid and substance P profiles in patients receiving emetogenic chemotherapy. J Oncol Pharm Practice 12:201-209
39. Campos D, Pereira JR, Reinhardt RR et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19:1759-1767
40. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high dose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
41. Herrstedt J, Muss HB, Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapyinduced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 104:1548-1555
42. Takahashi T, Hoshi E, Takagi M et al (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 101:2455-2461
43. Arrieta O, Michel Ortega RM et al (2010) Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: A prospective study. BMC Cancer 10:50
44. Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe hematological toxicity following chemotherapy. Ann Oncol 14:36-41
45. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-3051
46. Andreyev HJ, Norman AR, Oates J et al (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34:503-509
47. Blay JY, Chauvin F, Le Cesne A et al (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636-643
48. Kalra SP, Kalra PS (2003) Neuropeptide Y: A physiological orexigen modulated by the feedback action of ghrelin and leptin. Endocrine 22:49-56